Slate Path Capital’s Cue Biopharma CUE Stock Holding History

Slate Path Capital’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-80,082	Closed	-$1.82M	–	55
2024 Q3	$1.82M	Hold	80,082	–	–	0.03%	65
2024 Q2	$2.98M	Hold	80,082	–	–	0.06%	55
2024 Q1	$4.54M	Hold	80,082	–	–	0.09%	51
2023 Q4	$6.34M	Hold	80,082	–	–	0.14%	50
2023 Q3	$5.53M	Hold	80,082	–	–	0.15%	42
2023 Q2	$8.77M	Hold	80,082	–	–	0.32%	36
2023 Q1	$8.58M	Hold	80,082	–	–	0.4%	32
2022 Q4	$6.85M	Buy	80,082 +30,628	+62%	+$2.8M	0.37%	32
2022 Q3	$3.31M	Hold	49,454	–	–	0.22%	37
2022 Q2	$3.69M	Hold	49,454	–	–	0.23%	36
2022 Q1	$7.24M	Hold	49,454	–	–	0.37%	30
2021 Q4	$16.8M	Hold	49,454	–	–	0.88%	24
2021 Q3	$21.6M	Hold	49,454	–	–	0.99%	25
2021 Q2	$17.3M	Hold	49,454	–	–	0.97%	22
2021 Q1	$18.1M	Hold	49,454	–	–	1.17%	15
2020 Q4	$18.6M	Hold	49,454	–	–	1%	16
2020 Q3	$22.3M	Buy	49,454 +20,431	+70%	+$11.8M	1.27%	17
2020 Q2	$21.3M	Hold	29,023	–	–	1.26%	15
2020 Q1	$12.4M	Sell	29,023 -644	-2%	-$312K	0.95%	15
2019 Q4	$14.1M	Hold	29,667	–	–	0.76%	17
2019 Q3	$7.5M	Buy	+29,667	New	+$7.13M	0.5%	17

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

GLA

Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Slate Path Capital's CUE Position: Q4 2024 in Review

Slate Path Capital sold out of Cue Biopharma (CUE) in Q4 2024, closing a stake of 80,082 shares — an estimated $1.82M sold.

Slate Path Capital first reported a position in CUE in Q3 2019 and held it in 21 quarters. The position peaked at $22.3M in Q3 2020. 54 funds tracked by Wall St. Rank hold CUE as of Q4 2024.

Slate Path Capital reported no remaining Cue Biopharma position as of Q4 2024 after selling out during the quarter.
Slate Path Capital sold 80,082 Cue Biopharma shares in Q4 2024, an estimated $1.82M.
Slate Path Capital first reported a position in Cue Biopharma in Q3 2019 and held it in 21 quarters.
Slate Path Capital's Cue Biopharma position peaked at $22.3M in Q3 2020.
54 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2024.

Based on Slate Path Capital's 13F filing for Q4 2024, filed 14 Feb 2025.